RETATRUTIDE 10mg

Our Star Research Product

Retatrutide (LY3437943) is a next-generation, synthetic, lipidated peptide engineered as a triple hormone receptor agonist, targeting the GIP, GLP-1, and glucagon receptors. It represents a distinctive example of multi-receptor peptide pharmacology and is currently one of the most extensively studied investigational peptides in modern metabolic research.

Retatrutide is being investigated in extensive clinical development programs by Eli Lilly, including Phase 3 studies across obesity, type 2 diabetes, and related conditions. As of 2026, it remains an investigational compound and is not an FDA-approved medicine.

Alph4Labs’ Retatrutide 10mg is supplied as a research compound with batch-specific analytical documentation supporting identity, purity, and traceability. It is intended strictly for laboratory and scientific research and is not supplied as a pharmaceutical product or for human administration.

Scientific Name

Retatrutide (LY3437943) — synthetic lipidated triple hormone receptor agonist

Targets:

• GIP receptor (GIPR)

• GLP-1 receptor (GLP-1R)

• Glucagon receptor (GCGR)

Peptide: 39-amino-acid modified peptide with a C20 fatty-acid-based lipid moiety and additional structural modifications designed to influence receptor activity and pharmacokinetic properties.

Sequence representation:Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-[lipidated Lys]-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂

Specifications

• Product: Retatrutide / LY3437943

• Quantity: 10mg

• Form: Lyophilized research compound

• CAS Number: 2381089-83-2

• Molecular Weight: approximately 4,731 g/mol for the sodium form*

• Purity: >99% UK independent external laboratory verified*

• Storage: Refrigerated and protected from light

• Traceability: Unique batch reference

• Documentation: Batch-specific analytical verification

The molecular specification of retatrutide varies according to the exact chemical form. PubChem reports approximately 4,731 g/mol for retatrutide sodium, while related representations may differ depending on counterion and formulation. The exact molecular formula, molecular weight, and salt/form should therefore be taken directly from the applicable batch-specific CoA.

Research Grade

Retatrutide is currently a major subject of research into multi-receptor peptide pharmacology, particularly the coordinated activation of GIP, GLP-1, and glucagon receptors.

Its development program includes extensive investigation of metabolic and endocrine signaling, receptor pharmacology, molecular mechanisms, and clinical pharmacology. Lilly has reported positive results from multiple pivotal Phase 3 studies in 2026 and has stated plans to submit a Biologics License Application to the FDA in Q1 2027.

These clinical research results should not be interpreted as an indication that the Alph4Labs research product is an approved pharmaceutical or suitable for human use.

Why Retatrutide?

Triple-Receptor Research

Unlike single- or dual-receptor peptide agonists, retatrutide is designed to interact with three distinct hormone receptors — GIPR, GLP-1R and GCGR — within a single peptide molecule. This makes it a particularly relevant compound for research into multi-receptor pharmacology and complex metabolic signaling.

Advanced Peptide Engineering

Retatrutide incorporates amino-acid modifications and lipidation within its molecular architecture. These structural features are part of the molecule's engineered pharmacological profile and make it a technically sophisticated research peptide.

Extensively Studied

Retatrutide has progressed through extensive clinical development, including multiple Phase 3 programs during 2026. Its continued investigation provides a substantial scientific and clinical research base for studying triple-receptor agonism.

Highlights

• ⭐ ALPH4LABS STAR PRODUCT

• ⭐ 10mg Research Presentation

• FREE Shipping on all products

• Ships within 24 hours

• >24 months shelf life*

• >99% purity — independently verified by a UK external laboratory*

• Batch-specific traceability

• Analytical documentation supporting identity and purity

• Advanced 39-amino-acid lipidated peptide

• Triple-receptor research profile: GIPR / GLP-1R / GCGR

• One of the most extensively investigated next-generation multi-receptor peptides

• Controlled handling and storage
  

PRODUCT USE DISCLAIMER

For research purposes only.

Retatrutide supplied by Alph4Labs is intended strictly for laboratory and scientific research. It is not intended for human or veterinary use, self-administration, consumption, diagnosis, treatment, prevention of disease, or use as a pharmaceutical, nutritional, dietary, or therapeutic product.

Retatrutide is an investigational compound and is not currently represented by Alph4Labs as an FDA-approved medicine. Alph4Labs does not represent this research product as an Eli Lilly pharmaceutical product or as equivalent to any approved medicine.

Clinical research findings regarding retatrutide do not establish that an Alph4Labs research product is safe, effective, or suitable for human administration.

*Purity, shelf life, analytical testing, storage specifications, molecular form, and exact molecular weight should be verified against the applicable batch-specific Certificate of Analysis (CoA).